The EGFR/HER2 signaling network emerges as an effective therapeutic target in lung, colon, pancreas, head/neck and breast tumors. Over the last five years our laboratory studied the HER2 subtype of breast cancer and highlighted functional features, which collectively confer robustness (outcome reproducibility) and plasticity (secondary resistance) to the HER2 network [Citri and Yarden (2006) Nature Reviews Molec. Cell Biol.]. Alongside, we demonstrated several novel strategies capable of intercepting the EGF-to-EGFR/HER2 pathway (e.g., antibody combinations, soluble chimeric receptors and anti-ligand antibodies). Our current working hypothesis assumes that the EGFR/HER2 network plays a driving role not only in the HER2 subtype of breast cancer, but also in the similarly aggressive basal-like subtype. Consistent with this proposition, EGFR is almost ubiquitously expressed in basal-like tumors, and according to a recent comprehensive study of expression profiles, almost all tumors of this class express EGFR-associated, poor prognostic signatures. If validated, the working model predicts that anti-EGFR/HER2 therapies may have broader than expected value in breast cancer therapy. Hence, over the next five years we will focus on both the HER2 and the basal-like subtypes and address collaborating biochemical mechanisms, as well as prospects for new targeted therapies. Our first task entails construction of relevant cellular model systems, expressing either an active form of EGFR, or an amplified HER2, on the genetic background of normal basal-like cells. In the next step, we will study the respective three-dimensional spheroids by extracting both genetic and proteomic signatures, as well as by introducing collaborative genetic events. For example, loss of expression of p53, PTEN, BRCA1 and Rb (basal-like models) and co-amplified, chromosome 17 genes (HER2 models). Our therapeutic task will extend the experimental armamentarium by developing EGFR/HER2-specific aptamers and testing them in tumor-bearing animals, either side by side or in combination with decoy receptors and other novel therapies we established over the last five years.

Public Health Relevance

Breast cancer presents two unmet issues: Firstly, only a fraction of HER2 tumors respond to Trastuzumab, and secondary resistance limits efficacy. Secondly, no drugs effectively control basal-like cancer. By addressing collaborative mutations and the roles for stroma, our studies will shed light on mechanisms underlying aggressiveness of both subtypes. Our experimental therapeutic task will translate the results into novel strategies taraetino EGFR and HER2 in the context of both subtypes of tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA072981-16
Application #
8246949
Study Section
Special Emphasis Panel (NSS)
Program Officer
Salnikow, Konstantin
Project Start
1997-04-25
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
16
Fiscal Year
2012
Total Cost
$230,201
Indirect Cost
$17,052
Name
Weizmann Institute of Science
Department
Type
DUNS #
600048466
City
Rehovot, Israel
State
Country
Israel
Zip Code
76100
Schneider, Marlon R; Yarden, Yosef (2014) Structure and function of epigen, the last EGFR ligand. Semin Cell Dev Biol 28:57-61
Feldman, Morris E; Yarden, Yosef (2014) Steering tumor progression through the transcriptional response to growth factors and stroma. FEBS Lett 588:2407-14
Maron, Ruth; Schechter, Bilha; Mancini, Maicol et al. (2013) Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A 110:15389-94
Mahlknecht, Georg; Maron, Ruth; Mancini, Maicol et al. (2013) Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A 110:8170-5
Ferraro, Daniela A; Gaborit, Nadege; Maron, Ruth et al. (2013) Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A 110:1815-20
Emde, A; Pradeep, C-R; Ferraro, D A et al. (2011) Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 30:1631-42
Witsch, Esther J; Mahlknecht, Georg; Wakim, Jean et al. (2011) Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int Immunol 23:391-403
Zwang, Yaara; Sas-Chen, Aldema; Drier, Yotam et al. (2011) Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell 42:524-35
Zeisel, Amit; Kostler, Wolfgang J; Molotski, Natali et al. (2011) Coupled pre-mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Mol Syst Biol 7:529
Lindzen, Moshit; Lavi, Sara; Leitner, Orith et al. (2010) Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci U S A 107:12559-63

Showing the most recent 10 out of 55 publications